51ºÚÁϳԹÏÍø

ISSN: 2476-2067

Toxicology: 51ºÚÁϳԹÏÍø
51ºÚÁϳԹÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

51ºÚÁϳԹÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • Toxicol 51ºÚÁϳԹÏÍø 2023, Vol 9(5): 230
  • DOI: 10.4172/2476-2067.1000230

Paediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A Pharmacotherapy

Robert Mahmoud*
Department of Environmental Toxicology, Sao Paulo State University, Brazil
*Corresponding Author : Robert Mahmoud, Department of Environmental Toxicology, Sao Paulo State University, Brazil, Email: robert.mahmoud@gmail.com

Received Date: Sep 03, 2023 / Published Date: Sep 30, 2023

Abstract

Paediatric neurogenic bladder is a complex condition resulting from disrupted communication between the brain and the bladder, often caused by neurological disorders such as spina bifida, cerebral palsy, and spinal cord injuries. When conventional treatments prove inadequate, intravesical botulinum toxin type A pharmacotherapy has emerged as a promising intervention. This article explores the mechanism, benefits, considerations, and potential future directions of intravesical BoNT-A pharmacotherapy for paediatric neurogenic bladder. By temporarily relaxing overactive bladder muscles, BoNT-A injections offer symptomatic relief, improved bladder function, and the potential to prevent complications. As ongoing research refines administration techniques and dosages, intravesical BoNT-A pharmacotherapy may play an increasingly important role in enhancing the quality of life for paediatric patients with neurogenic bladder.

Citation: Mahmoud R (2023) Paediatric Neurogenic Bladder Intravesical BotulinumToxin Type A Pharmacotherapy. Toxicol 51ºÚÁϳԹÏÍø 9: 230. Doi: 10.4172/2476-2067.1000230

Copyright: © 2023 Mahmoud R. This is an open-access article distributed underthe terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Tools
Article Usage
  • Total views: 1285
  • [From(publication date): 0-2023 - Jun 24, 2025]
  • Breakdown by view type
  • HTML page views: 1020
  • PDF downloads: 265
International Conferences 2025-26
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top